Stielow, M.; Fijałkowski, Ł.; Alaburda, A.; Grześk, G.; Grześk, E.; Nowaczyk, J.; Nowaczyk, A.
SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology. Molecules 2025, 30, 3112.
https://doi.org/10.3390/molecules30153112
AMA Style
Stielow M, Fijałkowski Ł, Alaburda A, Grześk G, Grześk E, Nowaczyk J, Nowaczyk A.
SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology. Molecules. 2025; 30(15):3112.
https://doi.org/10.3390/molecules30153112
Chicago/Turabian Style
Stielow, Marlena, Łukasz Fijałkowski, Aidas Alaburda, Grzegorz Grześk, Elżbieta Grześk, Jacek Nowaczyk, and Alicja Nowaczyk.
2025. "SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology" Molecules 30, no. 15: 3112.
https://doi.org/10.3390/molecules30153112
APA Style
Stielow, M., Fijałkowski, Ł., Alaburda, A., Grześk, G., Grześk, E., Nowaczyk, J., & Nowaczyk, A.
(2025). SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology. Molecules, 30(15), 3112.
https://doi.org/10.3390/molecules30153112
